Results 111 to 120 of about 59,200 (224)

Randomized Double-blind Controlled Trial: Benefits of Lactobacillus reuteri in Chronic Functional Constipation Patients

open access: yesThe Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy, 2015
Background: Chronic functional constipation is a common problem that affects between 15-25% of the population and cause symptoms and disorders that creates discomfort, morbidity, and high costs for health care.
Taolin Agustinus   +3 more
doaj  

Novel Symptom Subgroups in Patients With Irritable Bowel Syndrome Are Associated With Healthcare Utilisation in Secondary and Tertiary Care

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
In patients with IBS in secondary and tertiary care, latent class analysis model identified groups of individuals with more severe symptoms and greater impairments in quality of life at baseline and significantly higher rates of healthcare utilisation during longitudinal follow‐up. ABSTRACT Background & Aims Current classification systems for irritable
Vivek C. Goodoory   +12 more
wiley   +1 more source

Sustainability in Healthcare: The Role of Digital Technologies for Improving Patient Engagement

open access: yesBusiness Ethics, the Environment &Responsibility, EarlyView.
ABSTRACT Sustainability in healthcare is getting considerable research attention as systems worldwide tend to balance environmental, social, and economic factors. In this context, digital technologies have demonstrated significant potential to enhance engagement among different consumer groups across various industries.
Francesco Schiavone   +4 more
wiley   +1 more source

Task-Dependent Cortical Oscillatory Dynamics in Functional Constipation. [PDF]

open access: yesSensors (Basel)
Li J   +11 more
europepmc   +1 more source

Exploring the use of dalfampridine (4‐aminopyridine) for treatment of ataxia in cerebellar stroke

open access: yes
PM&R, EarlyView.
Arjun Kotwal   +4 more
wiley   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

open access: yesBritish Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti   +24 more
wiley   +1 more source

Focal therapy using a novel cooled laser device for prostate cancer: early trial results

open access: yesBJU International, EarlyView.
Objectives To determine the short‐term oncological results and safety of the ProFocal Laser Therapy for Prostate Tissue Ablation (PFLT‐PC) trial, the first phase II clinical trial of ProFocal® (Medlogical Innovations, Sydney, Australia), a novel, cooled laser focal therapy (cLFT) device for prostate cancer (PCa) treatment. Patients and Methods Men with
Jonathan Kam   +17 more
wiley   +1 more source

Novel therapeutic targets for chronic visceral pain in gastrointestinal disorders

open access: yesBritish Journal of Pharmacology, EarlyView.
Chronic visceral pain imposes a major clinical challenge in gastroenterology and beyond, profoundly impacting patients' quality of life. However, limited understanding of its complex, multifaceted pathophysiology, encompassing both peripheral and central mechanisms, continues to impede the development of effective management strategies.
Fleur Veldman   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy